Abstracts tagged "Genetic Biomarkers"

Abstract Number: 1904 • 2013 ACR/ARHP Annual Meeting
Gene Expression In Whole Blood Predicts The Abatacept–Methotrexate Combination Responsiveness In Rheumatoid Arthritis: Preliminary Results From The Power Doppler Ultrasonography IM101-179 Study
T Lequerré¹, C Derambure¹, Maria-Antonietta d'Agostino², M Hiron³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq¹, ¹Rouen University Hospital & Inserm U905, Rouen, France, ²AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ³Rouen University Hospital & Inserm, Rouen, France, ⁴CHU Hôpital Sud, Grenoble, France, ⁵Bristol-Myers Squibb, Rueil Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: The overall response rate (defined as low disease activity [LDA] related to DAS28[CRP]) to abatacept associated with MTX was 57.1% at 6 months in…
Abstract Number: 1396 • 2013 ACR/ARHP Annual Meeting
Survivin–positivity Increases Risk For RA and Has a Strong Additive Effect On The Shared Epitope Alleles and Antibodies To Citrullinated Peptides In Patients Of The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis (MyEIRA) Study Group
Chun Lai Too¹, Shahnaz Murad², Malin Erlandsson³, Heselynn Hussein⁴, Wahinuddin Sulaiman⁵, Jasbir Singh Dhaliwal¹ and Maria Bokarewa³, ¹Institute for Medical Research, Allergy and Immunology Research Center, Jalan Pahang, Kuala Lumpur, Malaysia, ²Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia, ⁵Department of Medicine, Tengku Bainun Hospital, Ipoh, Perak, Malaysia
Background/Purpose: The human leukocyte antigen (HLA)-DRB1 with alleles that contain common amino acid motif QKRAA termed shared epitope (SE) confer the major locus of genetic…
Abstract Number: 1202 • 2013 ACR/ARHP Annual Meeting
Two Family Kindreds With Blau’s Syndrome Associated With Unusual NOD2 Mutations
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: The aim of this study was to report families of Blau’s syndrome with unusual NOD2 gene variants. Methods: Two proband patients were seen, and their clinical…
Abstract Number: 1201 • 2013 ACR/ARHP Annual Meeting
A Progress Report On An Emerging Disease: NOD2-Associated Autoinflammatory Disease
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: We recently reported a new disease designated as NOD2-associated autoinflammatory disease (NAID). The aim of this study was to update the progress on defining the disease. Methods: A…
Abstract Number: 1211 • 2013 ACR/ARHP Annual Meeting
Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever?
Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Familial Mediterranean fever (FMF) is traditionally regarded as an autosomal recessive disease characterized by periodic fever, serositis, erysipelas-like erythema and good response to colchicine. The…
Abstract Number: 687 • 2013 ACR/ARHP Annual Meeting
Role Of Class II Human Leukocyte Antigens In The Progression From Early To Definite Systemic Sclerosis
Barbara Vigone¹, Alessandro Santaniello², Maurizio Marchini¹, Gaia Montanelli¹, Monica Caronni¹, Adriana Severino¹, Stefania Celeste¹ and Lorenzo Beretta³, ¹Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Background/Purpose: Criteria for the diagnosis of Early Systemic Sclerosis (EaSSc) have been formalized by LeRoy and Medsger in 2001 and later validated by Koenig et…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].